Abstract
Objective
It has been reported that aspirin and other non-steroidal anti-inflammatory drugs (NSAID) may protect against dementia of Alzheimer's type and/or vascular dementia. However, co-morbidity and the dose of aspirin may be critical. A major indication for low-dose aspirin is prophylaxis after stroke and transient ischaemic attacks, conditions that may obscure an anti-dementia effect by the drug. Alternatively, low-dose aspirin may be insufficient if the protective effect is due to an anti-inflammatory mechanism. The aim of this study was to assess whether high-dose or low-dose aspirin may protect against Alzheimer's dementia in subjects aged ≥80 years. For comparison, effects of (other) NSAID, paracetamol and d-propoxyphene were studied.
Methods
Global, cross-sectional, and longitudinal (1991–2000) epidemiological analyses of clinical, cognitive and drug treatment data on 702 individuals 80 years old or more (351 twin pairs of same sex), all alive at inclusion: mean age 83.9 years (80–99 years). Calculations were made with logistic regression of associations between use of various analgesics and cognitive function, after adjustment for age, gender, and cardiovascular and cerebrovascular diseases.
Results
Users of high-dose aspirin had significantly lower prevalence of Alzheimer's dementia and better-maintained cognitive function than non-users. There were numerically similar but not significant associations with use of low-dose aspirin and other NSAID. There were no such associations with use of either paracetamol or d-propoxyphene.
Conclusion
Aspirin might protect against Alzheimer's disease, but controlled trials are warranted.
Similar content being viewed by others
References
McGeer PL, Schultzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease. Neurology 47:425–432
Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID. Neurology 48:46–47
Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC (2002) The Cache County study investigators. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study. Neurology 59:880–886
Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bebbett HP, Brooks WS, Halliday GM(2000) Anti-inflammatory drugs protect against Alzheimer's disease at low doses. Arch Neurol 57:1586–1591
In't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MMB, Stricker BHC (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515–1521
Williams PS, Rands G, Orrel M, Spector A (2000) Aspirin for vascular dementia. Cochrane Database Syst Rev CD001296
McClearn GE, Johansson B, Berg S, Pedersen NL, Ahern F, Petrill SA, Plomin R (1997) Substantial genetic influence on cognitive abilities in twins 80 or more years old. Science 276:1560–1563
Cederlöf R, Lorich U (1978) (Untitled) in Nance WE, Allen G, Parisi P (eds) Twin research: Part C. Biology and epidemiology. Alan R. Liss, New York, pp 189–195
Simmons SF, Johansson B, Zarit SH, Ljungquist B, Plomin R, McClearn GE (1997) Selection bias in samples of older twins. A comparison between octogenarian twins and singletons in Sweden. J Aging Health 9:553–567
WHO Collaborating Centre for Drug Statistics Methodology (1996) Guidelines for ATC classification and DDD assignment. WHO, Oslo
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders DSM-IV, 4th edn. APA, Washington
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRA work group under the suspicies of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34:939–944
Román GC, Tatemichi TK, Erkinjuntti T, Cumming JL, Masdeu JC, Garcia JH, Amaducci l, Orgogoza JM, Brun A, Hofman A et al (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 43:250–260
Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
Nilsson SE, Johansson B, Berg S, Karlsson D, McClearn GE (2002) A comparison of diagnosis capture from medical records, self-reports, and drug registrations: a study in individuals 80 years and older. Aging Clin Exp Res 14:178–184
World Health Organization (1992) ICD-10. International statistical classification of diseases and health problems, 10th revised edn., WHO, Geneva
Johansson B, Zarit SH (1995) Prevalence and incidence of dementia in the oldest old: a longitudinal study of a population-based sample of 84–90-year-olds in Sweden. Int J Ger Psychiatry 10:359–366
McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21:195–218
McGeer PL (2000) Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging 17:1–11
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-III-R), 3rd edn., APA, Washington
Jonsson C-O, Molander L (1964) Manual of the CVB scales. Psykologi Förlaget, Stockholm
Dureman I, Sälde H (1959) Psychometric and experimental–psychological methods for clinical application (in Swedish). Almqvist & Wiksell, Uppsala
Wechsler D (1991) Manual for the Wechsler adult intelligence-scale revised. Psychological Corporation, New York
Thurstone LL, Thurstone TG (1949) Manual to SRA primary mental abilities. Science Research Associates, Chicago
Johansson B (1988) The MIR—memory in reality test. Psykologiförlaget AB, Stockholm
Johansson B, Zarit SH (1991) Dementia and cognitive impairment in the oldest-old: a comparison of two rating methods. Int Psychogeriatr Spring 12:29–38
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34:939–944
Acknowledgements
The OCTO Twin Study ("The Origins of Variance in the Old-Old: Octogenarian Twins") is an ongoing longitudinal study conducted at the Institute of Gerontology (IG), at the School of Health Sciences in Jönköping, Sweden, in collaboration with the Center for Developmental and Health Genetics at the Pennsylvania State University (PSU), USA, and the Department of Medical Epidemiology at the Karolinska Institute in Stockholm, Sweden. The authors are greatly indebted to the project assistants Lene Ahlbäck, Agneta Carlholt, Gunilla Hjalmarsson, Eva Georgsson and Anna-Lena Wetterholm who travelled throughout the country and examined the twins. Invaluable help in coordinating the study is provided by Inger Cronholm, Ingegerd Brandström at IG, and Elana Pyle at PSU. The authors are also grateful to hospital and health care archivists for their willingness to provide medical records and to Monica Tubbin for her administrative efforts in handling all the records. The study was supported by a grant from the National Institute on Aging (NIA: AG 08861).
Author information
Authors and Affiliations
Corresponding author
Appendices
Appendix 1
Evaluation of cognitive status and dementia in the OCTO Twin Study
A rating of cognitive status (Cognitive Rating, CR) was conducted on all subjects using the scale below. The CR represents a composite score and was used as a convenient way to summarise performance across the tests and to provide an evaluation of the person's overall memory and cognitive function, taking overall health and functioning into account.
-
1.
Intact—"normal"—memory and cognitive functioning (corresponding MMSE ≥26), sensory and motor function, overall health, and physical functioning were taken into account
-
2.
Mild dysfunction/questionable impairment: evidence of compromised memory and/or cognitive functioning, not meeting DSM-III-R criteria for dementia
-
3.
Mild impairment/dementia: meeting behavioural criteria for mild dementia [20]
-
4.
Moderate impairment/dementia: meeting behavioural criteria for moderate dementia DSM-III-R criteria [20]
-
5.
Severe impairment/dementia: meeting behavioural criteria for severe dementia [20]
The CR was based on a thorough review of memory and cognitive performance. The test battery encompassed:
-
1.
Orientation to own person (name, year of birth, current age)
-
2.
Self-ratings of memory and thinking (six questions)
-
3.
The Mini-Mental State Examination (MMSE), [14]
-
4.
The Information Test (A Swedish version of the WAIS Information Task [21]
-
5.
Figure Logic/Inductive Reasoning (SRB:2) [22]
-
6.
Block Design—Koh's Block Test ( SRB 3) [22]
-
7.
Verbal Meaning—Synonyms (SRB 1) [22]
-
8.
Digit—Symbol (A modified version of the speeded Symbol-Digit Substitution Test from the Wechsler Adult Intelligence Scale, WAIS, where subjects were instructed to give a verbal response, instead of a written) [23]
-
9.
Digit—Span, Forward and Backward test (WAIS) [23]
-
10.
Perceptual Speed—Psif [22]
-
11.
Thurstone's Picture Memory Test [24]
-
12.
Prose Recall (A Swedish language prose recall task similar to the prose passages in the Wechsler Memory Test (WMS) [23]
-
13.
The MIR Test including naming, free recall, recogntion and correspondence tasks [25]
-
14.
The Swedish Clock Test (including the three subtests: clock drawing, set the hands of a wooden clock with no numbers on the face to certain standard times, and set time to certain standard times [26]
-
15.
The Coin Test [26]
The CR was made in the context of the subject's overall health and physical functioning, including, e.g., sensory functioning and motor handicaps. Also, observations of test-taking behaviour and everyday functioning during the in-person testing sessions were presented and taken into account before determining a CR score. In this respect, the CR represent a clinical evaluation based on multiple sources of information.
Individuals rated with mild to severe impairment (3–5) and tentatively diagnosed as dementia or demented, were routinely given a diagnostic work-up, including a detailed interview with a key informant about memory and cognitive problems (onset, course and symptomatology), and a review of medical records. Findings were presented and discussed at a consensus diagnosis conference. Diagnoses were assigned following DSM-III-R criteria for dementia [20], the NINCDS/ADRDA criteria for Alzheimer's disease [27], and the NINDS-AIREN criteria for vascular dementia [13].
Appendix 2
Definitions and distinctions for examined diagnoses (codes within parentheses refer to ICD-10)
-
Myocardial infarction (I21–22): the diagnosis requires an increase of specific enzymes in conjunction with the typical clinical manifestations and/or an ECG-pattern with specific QRS-aberrations.
-
Angina pectoris (I20): prescription of nitrates is considered to be a valid evidence for the diagnosis. In cases where angina is observed in temporal connection with a myocardial infarction, only infarction is registered.
-
Congestive heart failure (I50) means dyspnea and oedema referable to heart disorders, and typically treated with diuretics and/or digitalis.
-
Arrhythmia (I44–49): a diagnosis of cardiac arrhythmia is determined only when medical records explicitly use arrhythmia as a diagnosis. That means that fibrillation and other rhythm disturbances in connection with ongoing congestive heart failure are not included. The chief indications are paroxysmal attacks and arrhythmia in conjunction with heart blocks or Adams-Stokes attacks.
-
TIA (transitory ischaemic attack) (G45): acute neurological symptoms <24 h. Diagnosis only on the basis of medical records.
-
Stroke (I61;I63–65) is accepted as a diagnosis from information in records as well as from self-reports, although the few cases diagnosed only from the latter source may include TIA attacks.
-
Venous thromboembolism (I121;I180) includes deep thrombosis of lower extremities and/or pulmonary embolism.
-
Peptic ulcer of stomach and duodenum (K25–26) is clinically diagnosed with fibre endoscopy or X-ray support. Self-reports are accepted as the base for diagnosis.
-
Dorsal pain (M54): the diagnosis is mainly based on self-reports. In cases where the diagnosis is derived from medical records it requires a specific treatment or X-ray documented spondylarthritis. For cases in which the X-ray confirms demineralisation and/or spontaneous fractures, the diagnosis is osteoporosis (M80–81).
-
Coxarthritis (M16) and gonarthritis (M17) as clinical diagnoses require an X-ray confirmation and/or surgical intervention. As for dorsal pain, coxarthritis also includes mild and less well-documented cases derived from self-reports. For gonarthritis only record information was available.
Rights and permissions
About this article
Cite this article
Nilsson, S.E., Johansson, B., Takkinen, S. et al. Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged ≥80 years. Eur J Clin Pharmacol 59, 313–319 (2003). https://doi.org/10.1007/s00228-003-0618-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0618-y